Novocure's Raised Outlook Implies A Fourth-Quarter Revenue Dip, And The CFO Walks Through Why

The company's $736 million to $743 million revenue guide implies a softer fourth quarter than the $193 million just reported.

Share
Novocure's Raised Outlook Implies A Fourth-Quarter Revenue Dip, And The CFO Walks Through Why

Novocure's raised full-year guidance implies fourth-quarter revenue below the quarter it just posted, and CFO Christoph Brackmann said on the company's Thursday earnings call that the outlook is built on repeating the third quarter minus a one-time gain. Novocure, which makes wearable devices that deliver electric fields meant to kill cancer cells, now expects $736 million to $743 million in 2026 net revenue.

The step-down math

A JPMorgan analyst said the new range implies fourth-quarter revenue of $185 million to $192 million, under the $193 million recorded in the third quarter, and asked what drives the drop.

Brackmann said the third quarter added about $9 million to the record set in the second. Repeating it in the fourth quarter, less roughly $4.4 million of one-time revenue, gets to about $740 million for the year, around the guidance midpoint. The company then allowed for "some potential risk on collections" alongside some opportunities, he said.

He said the one-time benefit came from higher approval rates in the U.S. and Germany. Management put full-year growth at 12% to 13%.

Profit path, with a caveat

Third-quarter net revenue rose 16% from a year earlier, driven by a 19% rise in active patients, Brackmann said. Net loss narrowed to $10 million from $37 million, and adjusted EBITDA reached $15.7 million, according to coverage of the company's release. Gross margin was 77%, against 73% a year earlier.

Asked by an Evercore ISI analyst whether that profit level is sustainable, Brackmann said results will fluctuate and he wouldn't "want to commit to a straight line on a quarter-to-quarter basis." The fourth quarter is typically hard to estimate, he said, because the company is preparing next year's launches.

Pancreatic launch hits resistance

Optune Pax, the pancreatic cancer device, ended the quarter with 276 active patients and $3.7 million in net revenue. CEO Frank Leonard said U.S. momentum slowed after the introduction of a rival drug, and that practices are overwhelmed by insurance appeals and skin irritation, which limits the sales team's access.

Optune Lua, for lung cancer, had 255 active patients and $8 million in revenue, with Japan contributing 110 patients and $4 million. Leonard said Japanese reimbursement for Pax is likely in the first quarter of 2027.

The next catalyst is the FDA decision on Optune Maya for brain metastases from non-small cell lung cancer, which management expects by year end.

Management expects an FDA decision on Optune Maya by year end, with a potential launch in early 2027.

Sources

More on Novocure

All Novocure (NVCR) coverage →